• 15 August 2018

    TLC doses first patients in Phase I/II study of TLC590

    Taiwan Liposome Company (TLC) has dosed the first patients in a Phase I/II trial to investigate TLC590 in comparison with free, non-liposomal ropivacaine when given as a single infiltrative local...